JBM  Vol.7 No.7 , July 2019
Functional Activity of Circulating Phagocytes as Potential Pretreatment Marker of Tumor Drug Resistance
Abstract: The aim of this work was a study of the functional activity of neutrophils and peripheral blood monocytes in rats with the transplanted Walker carcinosarcoma as potential predictors of the sensitivity of this tumor to doxorubicin treatment. This study provides an evidence that such indices of the functional activity of circulating phagocytes of the tumor-bearing rats as the quantity and the phagocytosis intensity of monocytes, as well as the intensity of ROS production by monocytes and neutrophils, may reflect the degree of sensitivity of the tumor to doxorubicin. So it was shown that the growth of the resistant tumor caused a significant increase of the number of circulating phagocytic cells and the intensity of phagocytosis by more than 100% (p < 0.001) compared with the corresponding indices of intact rats and rats with the parental variant of the tumor. The ability of blood mono-cytes and neutrophils of rats with a resistant tumor to produce ROS was also significantly different from that in intact rats and animals with the parental carcinosarcoma variant. The predictive value of these indices is especially important in the dynamic monitoring of the development of tumor drug resistance during long-term cancer chemotherapy. Considering the standard 2 - 3 week interval between the courses of cancer therapy and the short lifetime of circulating phagocytes, an assessment of the indices of their functional activity before each subsequent course can be considered as a pretreatment assessment. Meanwhile, further studies are needed to determine the spectrum of malignant neoplasms for which the degree of tumor drug resistance correlates with the functional activity of circulating phagocytes.
Cite this paper: Prokhorova, I. , Yurchenko, O. , Pyaskovskaya, O. , Todor, I. and Solyanik, G. (2019) Functional Activity of Circulating Phagocytes as Potential Pretreatment Marker of Tumor Drug Resistance. Journal of Biosciences and Medicines, 7, 1-15. doi: 10.4236/jbm.2019.77001.

[1]   Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424.

[2]   American Cancer Society (2017) Breast Cancer Facts & Figures 2017-2018. American Cancer Society, Inc., Atlanta.

[3]   Gonzalez-Angulo, A.M., Morales-Vasquez, F. and Hortobagyi, G.N. (2000-2013) Overview of Resistance to Systemic Therapy in Patients with Breast Cancer. Madame Curie Bioscience Database. Landes Bioscience, Austin.

[4]   Li, G., Guo, J., Shen, B.Q., Yadav, D.B., Sliwkowski, M.X., Crocker, L.M., et al. (2018) Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells. Molecular Cancer Therapeutics, 17, 1441-1453.

[5]   Eisenhauer, E.A., Therasse, P., Bogaerts, J., Schwartz, L.H., Sargent, D., Ford, R., et al. (2009) New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline (Version 1.1). European Journal of Cancer, 45, 228-247.

[6]   Duffy, M.J. (2012) Tumor Markers in Clinical Practice: A Review Focusing on Common Solid Cancers. Medical Principles and Practice, 22, 4-11.

[7]   Araki, K., Ito, Y., Fukada, I., Kobayashi, K., Miyagawa, Y., Imamura, M., Kira, A., et al. (2018) Predictive Impact of Absolute Lymphocyte Counts for Progression-Free Survival in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer Treated with Pertuzumab and Trastuzumab plus Eribulin or Nab-Paclitaxel. BMC Cancer, 18, 982.

[8]   Xue, L.B., Liu, Y.H., Zhang, B., Yang, Y.F., Yang, D., Zhang, L.W., et al. (2019) Prognostic Role of High Neutrophil-to-Lymphocyte Ratio in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Meta-Analysis. Medicine, 98, e13842.

[9]   Dirican, A., Varol, U., Kucukzeybek, Y., Alacacioglu, A., Erten, C., Somali, I., et al. (2014) Treatment of Metastatic Colorectal Cancer with or without Bevacizumab: Can the Neutrophil/Lymphocyte Ratio Predict the Efficiency of Bevacizumab? Asian Pacific Journal of Cancer Prevention, 15, 4781-4786.

[10]   Todor, I.N., Lukianova, N.Y., Shvets, Y.V., Lozovska, Y.V. and Chekhun, V.F. (2015) Metabolic Changes during Development of Walker-256 Carcinosarcoma Resistance to Doxorubicin. Experimental Oncology, 37, 19-22.

[11]   Pinegin, B.V., Yarilin, A.A., Simonova, A.V., et al. (2001) The Use of Flow Cytometry to Assess the Functional Activity of the Human Immune System. Manual for Laboratory Doctors, Moscow. (In Russian)

[12]   Korzhevsky, D.E. (2013) Morphological Diagnosis. Preparation of Material for Histological Examination and Electron Microscopy: A Guide. SPb: SpecLit. (In Russian)

[13]   Kruger, P., Saffarzadeh, M., Weber, A.N.R., Rieber, N., Radsak, M., von Bernuth, H., et al. (2015) Neutrophils: Between Host Defence, Immune Modulation, and Tissue Injury. PLOS Pathogens, 11, e1004651.

[14]   Wang, X., Qiu, L., Li, Z., Wang, X.Y. and Yi, H. (2018) Understanding the Multifaceted Role of Neutrophils in Cancer and Autoimmune Diseases. Frontiers in Immunology, 9, 2456.

[15]   Finisguerra, V., Di Conza, G., Di Matteo, M., Serneels, J., Costa, S., Thompson, A.A.R., et al. (2015) MET Is Required for the Recruitment of Anti-Tumoural Neutrophils. Nature, 522, 349-353.

[16]   Coffelt, S.B., Kersten, K., Doornebal, C.W., Weiden, J., Vrijland, K., Hau, C.-S., et al. (2015) IL-17-Producing γ δ T Cells and Neutrophils Conspire to Promote Breast Cancer Metastasis. Nature, 522, 345-348.

[17]   Grecian, R., Whyte, M.K.B. and Walmsley, S.R. (2018) The Role of Neutrophils in Cancer. British Medical Bulletin, 128, 5-14.

[18]   Benarafa, C. (2015) Tumor-Induced Inflammation Alters Neutrophil Phenotype and Disease Progression. Breast Cancer Research, 17, 135.

[19]   Patel, D.A., Xi, J., Luo, J., Hassan, B., Thomas, S., Ma, C.X., et al. (2019) Neutrophil-to-Lymphocyte Ratio as a Predictor of Survival in Patients with Triple-Negative Breast Cancer. Breast Cancer Research and Treatment, 174, 443-452.

[20]   Fujimoto, Y., Ozawa, H., Higuchi, T., Miyagawa, Y., Bun, A., Imamura, M., et al. (2019) Improved Prognosis of Low Baseline Neutrophil-to-Lymphocyteratio Is Significantly Exclusive in Breast Cancer Patients with High Absolute Counts of Lymphocytes. Molecular and Clinical Oncology, 10, 275-284.

[21]   Imamura, M., Morimoto, T., Egawa, C., Fukui, R., Bun, A., Ozawa, H., et al. (2019) Significance of Baseline Neutrophil-to-Lymphocyte Ratio for Progression-Free Survival of Patients with HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine. Scientific Reports, 9, Article No. 1811.

[22]   Dirican, N., Dirican, A., Anar, C., Atalay, S., Ozturk, O., Bircan, A., et al. (2016) New Inflammatory Prognostic Index, Based on c-Reactive Protein, the Neutrophil to Lymphocyte Ratio and Serum Albumin Is Useful for Predicting Prognosis in Non-Small Cell Lung Cancer Cases. Asian Pacific Journal of Cancer Prevention, 17, 5101-5106.

[23]   Botta, C., Barbieri, V., Ciliberto, D., Rossi, A., Rocco, D., Addeo, R., et al. (2013) Systemic Inflammatory Status at Baseline Predicts Bevacizumab Benefit in Advanced Non-Small Cell Lung Cancer Patients. Cancer Biology & Therapy, 14, 469-475.

[24]   Ethier, J.L., Desautels, D., Templeton, A., Shah, P.S. and Amir, E. (2017) Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Breast Cancer: A Systematic Review and Meta-Analysis. Breast Cancer Research, 19, 2.

[25]   Miao, Y., Yan, Q., Li, S., Li, B. and Feng, Y. (2016) Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio Are Predictive of Chemotherapeutic Response and Prognosis in Epithelial Ovarian Cancer Patients Treated with Platinum-Based Chemotherapy. Cancer Biomarkers, 17, 33-40.

[26]   Gordon, S. and Taylor, P.R. (2005) Monocyte and Macrophage Heterogeneity. Nature Reviews Immunology, 5, 953-964.

[27]   Sica, A., Porta, C., Morlacchi, S., Banfi, S., Strauss, L., Rimoldi, M., Totaro, M.G. and Riboldi, E. (2012) Origin and Functions of Tumor-Associated Myeloid Cells (TAMCs). Cancer Microenvironment, 5, 133-149.

[28]   Gyamfi, J., Eom, M., Koo, J.S. and Choi, J. (2018) Multifaceted Roles of Interleukin-6 in Adipocyte-Breast Cancer Cell Interaction. Translational Oncology, 11, 275-285

[29]   Mon, M.T., Yodkeeree, S., Punfa, W., Umsumarng, S., Lek-wanavijit, S., Siriaunkgul, S., et al. (2017) Relationships of Ex-Vivo Drug Resistance Assay and Cytokine Production with Clinicopathological Features in the Primary Cell Culture of Thai Ovarian and Fallopian Tube Cancer Patients. Asian Pacific Journal of Cancer Prevention, 18, 3063-3071.

[30]   Li, X.Y., Liao, X.F., Wang, H.B. and Zhang, J. (2018) Doxorubicin Resistance Induces IL6 Activation in the Colon Cancer Cell Line LS180. Oncology Letters, 16, 5923-5929.

[31]   Chen, Y., Liu, J., Lv, P., Gao, J., Wang, M. and Wang, Y. (2018) IL-6 Is Involved in Malignancy and Doxorubicin Sensitivity of Renal Carcinoma Cells. Cell Adhesion & Migration, 12, 28-36.

[32]   Zhang, Y., Choksi, S., Chen, K., Pobezinskaya, Y., Linnoila, I. and Liu, Z.G. (2013) ROS Play a Critical Role in the Differentiation of Alternatively Activated Macrophages and the Occurrence of Tumor-Associated Macrophages. Cell Research, 23, 898-914.